257 related articles for article (PubMed ID: 18829470)
21. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
22. NK3 and NK4 of HGF enhance filamin production via STAT pathway, but not NK1 and NK2 in human breast cancer cells.
Yin YL; Chen HL; Kuo HM; He SP
Acta Pharmacol Sin; 2008 Jun; 29(6):728-35. PubMed ID: 18501120
[TBL] [Abstract][Full Text] [Related]
23. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
[TBL] [Abstract][Full Text] [Related]
24. IGF-IR: potential role in antitumor agents.
Guerreiro AS; Boller D; Doepfner KT; Arcaro A
Drug News Perspect; 2006 Jun; 19(5):261-72. PubMed ID: 16941048
[TBL] [Abstract][Full Text] [Related]
25. A mathematical model of combination therapy using the EGFR signaling network.
Araujo RP; Petricoin EF; Liotta LA
Biosystems; 2005 Apr; 80(1):57-69. PubMed ID: 15740835
[TBL] [Abstract][Full Text] [Related]
26. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
27. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
28. The shadow of death on the MET tyrosine kinase receptor.
Tulasne D; Foveau B
Cell Death Differ; 2008 Mar; 15(3):427-34. PubMed ID: 17917681
[TBL] [Abstract][Full Text] [Related]
29. Src continues aging: current and future clinical directions.
Kopetz S; Shah AN; Gallick GE
Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
[TBL] [Abstract][Full Text] [Related]
30. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
31. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
32. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
33. Invasive growth: a genetic program.
Gentile A; Comoglio PM
Int J Dev Biol; 2004; 48(5-6):451-6. PubMed ID: 15349819
[TBL] [Abstract][Full Text] [Related]
34. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
[TBL] [Abstract][Full Text] [Related]
35. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.
Milella M; Kornblau SM; Andreeff M
Rev Clin Exp Hematol; 2003 Jun; 7(2):160-90. PubMed ID: 14763161
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice.
Wen J; Matsumoto K; Taniura N; Tomioka D; Nakamura T
Biochem Biophys Res Commun; 2007 Jun; 358(1):117-23. PubMed ID: 17467663
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Zou JN; Wang SZ; Yang JS; Luo XG; Xie JH; Xi T
Cancer Lett; 2009 Jul; 280(1):78-85. PubMed ID: 19321255
[TBL] [Abstract][Full Text] [Related]
38. c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration.
Provençal M; Labbé D; Veitch R; Boivin D; Rivard GE; Sartelet H; Robitaille Y; Gingras D; Béliveau R
Carcinogenesis; 2009 Jul; 30(7):1089-96. PubMed ID: 19359592
[TBL] [Abstract][Full Text] [Related]
39. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
40. Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells.
Ushio K; Hashimoto T; Kitamura N; Tanaka T
Mol Cancer Res; 2009 Jul; 7(7):1179-88. PubMed ID: 19567783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
